Quantifying emerging drugs for very rare conditions

Kathryn Miles, Claire Packer, Andrew Stevens

    Research output: Contribution to journalArticle

    10 Citations (Scopus)


    BACKGROUND: EU legislation is encouraging pharmaceutical companies to develop drugs for rare conditions, but their often high cost, and potential for long-term administration has led to debate about their affordability and cost-effectiveness. AIM: To investigate how many drugs are in development for very rare conditions. METHODS: We defined very rare conditions as having a prevalence of
    Original languageEnglish
    Pages (from-to)291-295
    Number of pages5
    Early online date27 Mar 2007
    Publication statusPublished - 27 Mar 2007


    Dive into the research topics of 'Quantifying emerging drugs for very rare conditions'. Together they form a unique fingerprint.

    Cite this